Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Cancer cell | Sep 2, 2003

http://www.ncbi.nlm.nih.gov/pubmed/14522256

Increased Myc gene copy number is observed in human prostate cancer. To define Myc's functional role, we generated transgenic mice expressing human c-Myc in the mouse prostate. All mice developed murine prostatic intraepithelial neoplasia followed by invasive adenocarcinoma. Microarray-based expression profiling identified a Myc prostate cancer expression signature, which included the putative human tumor suppressor NXK3.1. Human prostate tumor databases revealed modules of human genes that varied in concert with the Myc prostate cancer signature. This module includes the Pim-1 kinase, a gene known to cooperate with Myc in tumorigenesis, and defines a subset of human, "Myc-like" human cancers. This approach illustrates how genomic technologies can be applied to mouse cancer models to guide evaluation of human tumor databases.

Pubmed ID: 14522256 RIS Download

Mesh terms: Adenocarcinoma | Androgens | Animals | Gene Expression Profiling | Gene Expression Regulation, Neoplastic | Genes, myc | Homeodomain Proteins | Humans | Male | Mice | Mice, Transgenic | Neovascularization, Pathologic | Orchiectomy | Prostate | Prostatic Intraepithelial Neoplasia | Prostatic Neoplasms | Protein-Serine-Threonine Kinases | Proto-Oncogene Proteins | Proto-Oncogene Proteins c-pim-1 | Transcription Factors

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

None

Mouse Genome Informatics (Data, Gene Annotation)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.